Ketamine does carry addictive potential, but the risk is significantly lower in supervised clinical settings than with recreational use. The key difference comes down to dose, frequency, and control: therapeutic ketamine is given in small amounts, on a strict schedule, under direct medical observation. That said, the risk isn’t zero, and the safeguards built into clinical ketamine programs exist precisely because the drug can produce dependence.
Why Ketamine Has Addictive Properties
Ketamine produces dissociative and sometimes euphoric effects, which is the core reason it has abuse potential. It’s classified as a Schedule III controlled substance in the United States. Beyond its well-known effects on a brain chemical called glutamate, ketamine also interacts with the brain’s opioid system. Research published in the American Journal of Psychiatry found that naltrexone, a drug that blocks opioid receptors, actually interfered with ketamine’s antidepressant effects. This opioid connection doesn’t mean ketamine works exactly like painkillers, but it does suggest the drug engages some of the same reward pathways that make other substances habit-forming.
Tolerance can develop with frequent use, meaning more of the drug is needed to achieve the same effect. In recreational users who take ketamine daily or near-daily, this tolerance escalates quickly. In clinical settings, tolerance is less of a concern because the dosing schedule is far more spread out.
How Clinical Use Limits the Risk
Therapeutic ketamine programs are structured to minimize addiction risk at every step. A typical treatment course starts with an induction phase of six to eight infusions, each delivered intravenously over about 40 minutes. After that, patients move to a maintenance phase where doses are spaced roughly three weeks apart. Compare that to recreational users who may take the drug multiple times per week or even daily, and the exposure gap is enormous.
The FDA-approved nasal spray form, esketamine (sold as Spravato), goes even further. It’s available only through a restricted distribution program that requires certified healthcare settings, direct observation during every dose, and a mandatory two-hour monitoring period afterward. You cannot take it home. Pharmacies can only dispense it to certified clinics, not directly to patients. Before starting treatment, clinicians are required to assess your risk for abuse or misuse, and they continue monitoring for drug-seeking behavior throughout the course of therapy.
IV ketamine clinics, which operate outside the Spravato program, have fewer federally mandated restrictions but generally follow professional guidelines. The American Psychiatric Nurses Association recommends urine drug screening before and during treatment, a comprehensive substance use history, and exclusion of patients with active substance abuse from ketamine therapy.
What Withdrawal Can Look Like
Withdrawal from ketamine is not as well-documented as withdrawal from opioids or alcohol, but it does happen. Regular users who stop abruptly can experience anxiety, low mood, cravings, tremors, irritability, and disrupted sleep. A case reported in the American Journal of Psychiatry described a patient receiving ketamine for depression who became increasingly agitated, dysphoric, and suicidal when he couldn’t afford his treatments and went a day or two without the drug. He described an intense, agitated state that only resolved when he resumed ketamine.
This case is notable because it involved someone using ketamine therapeutically, not recreationally. The patient was spending $600 per month on treatment, and the irregular access created a pattern of use and withdrawal that resembled dependence. It’s a single case report, not a common outcome, but it illustrates that even medically motivated use can sometimes lead to problematic dependence, particularly when treatment becomes inconsistent.
Who Faces Higher Risk
People with a history of substance use disorder are at greater risk for developing problematic ketamine use. The FDA’s prescribing information for Spravato explicitly states that individuals with past drug abuse or dependence require “careful consideration” before treatment. Most clinics will screen for this before starting you on ketamine, and some will decline to treat patients with active addiction to alcohol, cannabis, or other substances.
The risk also rises when treatment moves outside structured medical settings. Patients who obtain ketamine from compounding pharmacies for at-home use, for example, face fewer built-in safeguards. Without the controlled environment of a clinic, the line between therapeutic and self-directed dosing can blur, especially for someone already struggling with mood instability.
Putting the Risk in Context
The addiction risk of clinical ketamine is real but modest when treatment follows established protocols. The vast majority of patients receiving supervised ketamine infusions or Spravato for depression do not develop substance use disorders. The concern is less about a single course of treatment and more about long-term maintenance, where repeated exposure over months or years creates more opportunity for tolerance and psychological dependence to develop.
If you’re considering ketamine for depression, the most protective factors are a structured clinical setting, a provider who screens for substance use history, consistent dosing intervals, and ongoing monitoring. The drug’s addictive potential doesn’t disqualify it as a treatment, but it does mean the conditions under which you receive it matter as much as the medication itself.